BMS Opdivo and Yervoy combo misses primary endpoint in Phase III NSCLC trial
The Phase III trial pitted Opdivo and Yervoy combination therapy with chemoradiation against AstraZeneca’s Imfinzi and chemoradiation therapy.
The Phase III trial pitted Opdivo and Yervoy combination therapy with chemoradiation against AstraZeneca’s Imfinzi and chemoradiation therapy.
The FDA granted de novo classification to the Symani Surgical System for soft tissue manipulation in microsurgery in April 2024.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
“Defensibility” key for AI-centric small biotechs seeking investment
Klineo wins €2m to advance AI patient recruitment platform
Hyperfine starts enrolment in portable imaging workflow study
Acarix starts clinical workflow study for its AI-powered cardiac diagnostic